Prevalence of Antimicrobial Resistance in Tanzania: A Systematic Review and Meta-Analysis

Charles B. Kafaiya[1*], Johnson J. Mshiu[1], Obadia Bishoge[1,2], Jonathan M. Mshana[1], Sia Malekia[1], Irene Mremi[1], Angelina M. Lutambi[1], Mwanaada Kilima[3], Mary Mayige[1], Said Aboud[1,4]

Authors Affiliations

[1]National Institute for Medical Research (NIMR), Dar es Salaam, Tanzania
[2]Department of Environmental and Occupational Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
[3]Muhimbili National Hospital, Dar es Salaam, Tanzania
[4]Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

[*]**Corresponding author**

E-mail: charles.kafaiya@nimr.or.tz (CBK)

Abstract

Antimicrobial resistance (AMR) threatens global health. Understanding resistance patterns aids in treatment and promotes responsible antimicrobial use. This review and meta-analysis assessed the prevalence of antimicrobial resistance among clinically relevant pathogens in Tanzania. A total of 18,265 studies identified from Google Scholar (18,000), PubMed (13), and Science Direct (252) underwent screening and full article review. Finally, 28 studies were included. A subgroup analysis was performed to evaluate the resistance patterns within antibiotic classes for specific pathogens. Descriptive statistics were used to describe the characteristics of the studies

and the prevalence of antibiotic resistance. Heterogeneity was assessed using forest plots and the I^2 statistic. Among the included studies, most isolates (25.0%) were obtained from urine samples. Of these studies, 75% were cross-sectional studies and 92.9% were conducted in hospital settings. The analysis revealed high resistance to penicillin, particularly amoxicillin-clavulanic and ampicillin, with Klebsiella pneumoniae (0.96 [0.83–0.99]), Acinetobacter baumannii (0.94 [0.67–0.99]) and Escherichia coli (0.90 [0.81–0.95]). Similarly, erythromycin resistance was most prevalent in Campylobacter spp. (0.85 [0.80–0.89]). Ciprofloxacin resistance was highest in Acinetobacter baumannii (0.54 [0.33–0.73]), whereas amikacin resistance was highest in Proteus spp. (0.86 [0.35–0.99]). Ceftriaxone resistance was particularly high in Acinetobacter baumannii (0.91 [0.70–0.98]) and Pseudomonas aeruginosa (0.85 [0.74–0.92]). Resistance to meropenem was lowest among Escherichia coli (0.04 [0.01–0.10]) and Klebsiella spp. (0.07 [0.03–0.15]), with an overall pooled resistance to the ESKAPE-E pathogen of (0.11[0.06–0.19]). Imipenem and clindamycin each had an overall pooled resistance of (0.06[0.02-0.14]) against both Escherichia coli and Klebsiella pneumoniae. The findings highlight widespread resistance among key bacterial pathogens, ESKAPE-E, particularly in the *Access* and *Watch* groups of antibiotics. The variability in resistance patterns underscores the need to re-evaluate empirical treatment protocols (STG/NEMLIT) to ensure effective treatment regimens, strengthen antimicrobial stewardship, enhance surveillance systems, and promote rational antibiotic use.

Keywords: Antimicrobial resistance, ESKAPE-E, AWaRe, Tanzania

Introduction

Antimicrobial resistance occurs when pathogens resist exposure to antibiotics that are intended to kill or slow their growth (1,2). It has become one of the leading public health threats of the 21st century, posing significant dangers to global health, economic stability, and the effectiveness of healthcare systems (3). The World Health Organization (WHO) has recognised antimicrobial resistance as a serious public health concern that can result in prolonged hospital admissions, greater medical expenses and increased mortality rates (4). Furthermore, in 2017, the WHO identified ESKAPE pathogens; *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,* and *Enterobacter* species as major global health threats due to their rising antibiotic resistance and potential to cause serious infections in humans (2). This has made standard treatments less effective as bacterial pathogens change, making it more difficult to treat once-treatable infections. This phenomenon is particularly noticeable in low- and middle-income countries, where antibiotic abuse is pervasive, infectious disease burdens are high, and healthcare resources are scarce (3,5).

In Tanzania, the prevalence of antibiotic resistance has been increasingly documented; however, comprehensive data remain sparse (6,7). A variety of factors contribute to the rising rates of Antimicrobial Resistance (AMR) in the country, including over-prescription of antibiotics, self-medication, and inadequate regulatory frameworks for antibiotic use. Additionally, socio-economic factors such as personal awareness, attitudes, practices, poverty, lack of access to healthcare services, and poor sanitation and hygiene practices exacerbate the situation (8). The interplay of these factors creates an environment conducive to the emergence and spread of resistant strains of bacteria.

Despite the urgency of resistant pathogens, systematic reviews focusing specifically on Tanzania's antibiotic resistance landscape are limited. While several studies have reported resistance patterns for specific pathogens, a consolidated analysis that captures the overall prevalence across the country is needed. This knowledge gap hampers effective policymaking and public health interventions aimed at curbing antibiotic misuse and managing resistance. By combining the available data, this systematic review and meta-analysis aimed to present a thorough overview of the prevalence of antibiotic resistance in Tanzania. A rigorous analysis of the published studies was conducted to identify the prevalence of resistant pathogens among different antibiotics. This review will inform the National Action Plan on Antimicrobial Resistance 2023 -2028 to strengthen surveillance, infection control, and antibiotic resistance stewardship programs in the country.

Methodology

Protocol registration

The systematic review and meta-analysis protocol was registered with PROSPERO under the ID number PROSPERO 2024 CRD42024608537.

Settings

The evaluation was based on studies conducted in Tanzania, an East African country located in the African Great Lakes Region. It is bordered by Uganda to the northwest, Kenya to thee northeast, the Indian Ocean to the east, Mozambique and Malawi to the south, Zambia to the southwest, and Rwanda, Burundi, and the Democratic Republic of the Congo to the west. According to the 2022 national census, Tanzania has a population of approximately 62 million (9), making it the most populous country south of the equator. Antimicrobial resistance is a major

public health issue in Tanzania, with a high prevalence of multidrug-resistant microorganisms (10). In clinical settings, the prevalence of multidrug-resistant bacteria varies between 25% and 50% (11). Previous research has shown a significant prevalence of methicillin-resistant *S. aureus* and extended-spectrum beta-lactamase-producing bacteria (7). The risk factors for antimicrobial resistance in Tanzania include irrational antibiotic use, inadequate hygiene and sanitation, transmission, sociodemographic characteristics, patient clinical information, and admission to healthcare facilities (12,13).

Review procedures

The systematic review began by identifying the research question and was finalised with a report (14). The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for reviewing, analysing, and reporting systematic reviews (15), which covers all aspects of the manuscript, including the title, abstract, introduction, methods, results, and discussion.

Search strategy

Relevant published studies were searched using electronic databases such as PubMed, ScienceDirect, and Google Scholar. The following phrases were used for the search: (((("Prevalence"[Mesh] OR "Prevalences" OR "Point Prevalence" OR "Point Prevalences" OR "Prevalence, Point" OR "Period Prevalence" OR "Period Prevalences" OR "Prevalence, Period") AND ("Risk Factors"[Mesh] OR "Factor, Risk" OR "Risk Factor" OR "Population at Risk" OR "Populations at Risk" OR "Risk Scores" OR "Risk Score" OR "Score, Risk" OR "Risk Factor Scores" OR "Risk Factor Score" OR "Score, Risk Factor" OR "Health Correlates" OR "Correlates, Health" OR "Social Risk Factors" OR "Factors, Social Risk" OR "Risk Factor, Social" OR "Risk Factors, Social" OR "Social Risk Factor")) AND ("Drug Resistance,

Bacterial"[Mesh]OR "Antibacterial Drug Resistance" OR "Antibiotic Resistance, Bacterial"))

AND ("Tanzania"[Mesh] OR "United Republic of Tanzania" OR "Zanzibar").

Selection criteria and search outcomes

The following criteria were used to select relevant studies: (i) studies reporting on the prevalence of antibiotic resistance in bacterial pathogens; (ii) studies conducted in Tanzania over ten years, from 2014 to 2024; (iii) original cross-sectional studies, cohort studies, case-control studies, experimental studies, or modelling studies; and (iv) studies focused on antibiotic resistance. The review excluded studies that did not focus on antibiotic resistance, animal or laboratory-based studies without clinical relevance, reviews, letters, notes, editorials, and conference reports. This process yielded 18,265 articles related to the study topic. The studies were uploaded to Covidence, a web-based software (16) for screening, full article review, and data extraction. A total of 28 studies satisfied the set criteria and were included in this review (**Fig 1**).

Fig 1. Prisma flow chart of the systematic review and article selection.

Quality assessment

The included studies were evaluated for methodological quality and risk of bias using the Joanna Briggs Institute's Quality Assessment Tool for Cross-Sectional Studies (17,18). The studies were scored as Yes, No, Unclear, and Not applicable (**S1 Table**).

S1 Table: **Quality Assessment Table.**

Data synthesis, analysis and reporting

The data were independently extracted by two researchers, focusing on various characteristics of the studies involved. These characteristics included the author and year of publication, study area, study design, study population, sampling methods, sample size, isolate samples, sources of samples, type of bacteria/pathogen, and type of antibiotic used. Descriptive statistics were used to summarise the characteristics of the studies using frequency and percentage. A meta-analysis was performed to estimate the pooled prevalence rates of antibiotic resistance using random-effects models. Forest plots and I^2 statistics were used to evaluate heterogeneity among the studies, with higher values indicating significant heterogeneity (19). Subgroup analyses were conducted to investigate potential drug resistance in specific pathogens associated with each antibiotic. All analyses were conducted using the R libraries (meta) and (metafor) (20,21). Finally, the results were visually presented through tables and figures, including bar charts and plot forests.

Results

Study characteristics

Settings, study designs and year of publication of the selected studies

Of the 28 included studies, most (32%) were conducted in Dar es Salaam, followed by Mwanza (25%) and Kilimanjaro (17.9%), with 75.0% being cross-sectional. Additionally, 17.9% of the studies were published in 2020, while 14.3% were published in 2016, 2019, and 2022 (**Fig 2**).

Fig 2. Distribution of the Year of Publication, Study Design, and Region.

Study population, sample size and number of isolates

Most of the selected studies (46%) involved children under five years of age. The sample size of the selected studies ranged from 75 (22) to 4,306 (23), with the number of isolates ranging from 22 (24) to 4,030 (23) (**Table 1**). The most common clinical samples were urine (25%), nasopharyngeal swabs (10.7%), open wound pus swabs (7.1%), and blood (3.6%) (**Fig 3**).

Table 1: Study population, sampling methods, sample size, number of isolates and sample sources of the selected studies

Author	Study population	Sample Size	Number of Isolates
Manyahi et al., 2014 (25)	Patients with clinical evidence of SSI	100	147
Moyo et al., 2014 (26)	Healthy under-fives	114	114
Marwa et al., 2015 (27)	HIV/AIDS patients	945	155
Komba et al., 2015 (28)	Patients with enteric and non-enteric symptoms	1195	136
Ahmed et al., 2015 (29)	Malnourished under-fives	402	84
Okamo et al., 2016 (30)	Medical students	314	66
Moremi et al., 2016 (31)	More samples were from paediatric population	3330	439
Tellevik et al., 2016 (32)	Children Below 2 years	603	284
Seidman et al., 2016 (33)	Young children	377	2492
Ahmed et al., 2017 (34)	Malnourished under-fives	402	42
Joachim et al., 2017 (24)	Patients attended at EMD/IPD	258	22
Kumburu et al., 2017 (35)	Patient admitted in surgical and medical department	575	377
Kiponza et al., 2019 (36)	Post-delivery women	197	107
Seni et al., 2019 (37)	Pregnant women with significant bacteriuria	1828	323
Emgård et al., 2019 (38)	Children	775	244
Madut et al., 2019 (39)	Adolescent and adult patients aged ≥13 y with fever.	1648	31
Daud et al., 2020 (40)	Children	282	282
Kamgobea et al., 2020 (41)	Pregnant women with or without PROM	350	39
Mikomangwa et al., 2020 (42)	Patients attended	183	201
Manyahi et al., 2020 (43)	All inpatients with features suggestive of BSI	402	44
Kadigi et al., 2020 (44)	Under-fives with symptoms of UTI	270	80
Letara et al., 2021 (45)	Children	350	76
Sangeda et al., 2021 (46)	Under-fives with symptoms of UTI	214	35
Manyahi et al., 2022 (47)	Admitted patients	198	179
Masoud et al., 2022 (22)	Admitted patients	75	76
Schmider et al., 2022 (48)	Outpatients aged ≥2 years with symptoms of UTI	270	119

Silago et al., 2022 (49)	Patients who resided within the study area	1327	412
Muhiddin Hamada Omar 2024 (23)	Hospitalized patients	4306	4030

Fig 3. Sources of samples for selected studies.

Results from meta-analysis

The meta-analysis included 28 studies that investigated antibiotic resistance patterns across a broad spectrum of pathogens, including ESKAPE-E bacteria (*Escherichia coli, Staphylococcus*

aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and *Enterobacter spp.), Proteus spp., Streptococcus spp., Campylobacter spp.,* and *P. mirabilis.*

The review examined various pathogens against 17 antibiotics, including penicillin (amoxicillin and ampicillin), macrolides (erythromycin), fluoroquinolones (ciprofloxacin), aminoglycosides (amikacin), tetracyclines (tetracycline), sulphonamides (trimethoprim-sulfamethoxazole), and cephalosporins (2nd, 3rd and 4th generations). It also included carbapenems (meropenem and imipenem), lincosamides (clindamycin), and nitrofuran compounds (nitrofurantoin) (**S1-S14 Figs**) (**Fig. 4-6**).

A subgroup analysis was conducted to assess the resistance patterns within each antibiotic class for specific pathogens. The results revealed high resistance to penicillin (*amoxicillin–clavulanic acid*), with the highest pooled prevalence observed in *Acinetobacter baumannii* (0.92 [0.76–0.98]), followed by *Proteus mirabilis* (0.87 [0.63–0.96]), *Klebsiella pneumoniae* (0.85 [0.73–0.92]), and *Enterobacter spp.* (0.83 [0.61–0.94]). Resistance was also notable among *Escherichia coli* (0.61 [0.42–0.77]) and *Klebsiella spp.* (0.53 [0.20–0.84]) (**Fig 1**). Similarly, a high level of resistance to penicillin (ampicillin) was observed among ESKAPE-E pathogens and *Proteus* spp. The pooled prevalence of resistance ranged from *Klebsiella pneumoniae* (0.96 [0.83–0.99]), *Acinetobacter baumannii* (0.94 [0.67–0.99]), *Escherichia coli* (0.90 [0.81–0.95]), *Klebsiella* spp. (0.90 [0.81–0.95]), *Enterobacter cloacae* (0.78 [0.46–0.94]), *Pseudomonas aeruginosa* (0.77 [0.47–0.92]), *Proteus* spp. (0.76 [0.58–0.88]), and *Staphylococcus aureus* (0.76 [0.38–0.94]) (**S1 Fig**).

Fig 4. Amoxicillin/clavulanic acid resistance patterns among various pathogens.

Resistance to macrolides, specifically erythromycin, was highest among *Campylobacter spp.* (0.85 [0.80–0.89]), followed by *Escherichia coli* (0.61 [0.16–0.93]) and *Staphylococcus*

aureus (0.52 [0.35–0.68]) (**S2 Fig**). Ciprofloxacin exhibited a pooled resistance prevalence of 0.54 [0.33–0.73] in *Acinetobacter baumannii* (**S3 Fig**), whereas amikacin resistance was notably high in *Proteus spp.* (0.86 [0.35–0.99]) (**S4 Fig**). Tetracycline resistance was prevalent in *Klebsiella pneumoniae* (0.81 [0.24–0.98]) and *Escherichia coli* (0.77 [0.71–0.83]) (**S5 Fig**). Additionally, trimethoprim-sulfamethoxazole showed high resistance in *Klebsiella pneumoniae* (0.93 [0.77–0.98]), *Escherichia coli* (0.86 [0.75–0.93]), and *Proteus mirabilis* (0.80 [0.30–0.97]) (**S6 Fig**).

The pathogens exhibiting the highest resistance to ceftriaxone, a third-generation cephalosporin, include *Acinetobacter baumannii* (0.91 [0.70–0.98]), *Proteus mirabilis* (0.71 [0.47–0.87]), *Klebsiella species* (0.65 [0.40–0.84]), *Klebsiella pneumoniae* (0.74 [0.59–0.85]), and *Pseudomonas aeruginosa* (0.85 [0.74–0.92]) (**Fig 2**). Similarly, high resistance to cefotaxime was observed in *Acinetobacter baumannii* (0.92 [0.53–0.99]), *Pseudomonas aeruginosa* (0.90 [0.53–0.99]), *Klebsiella pneumoniae* (0.94 [0.62–0.99]), *Escherichia coli* (0.81 [0.35–0.97]), and *Proteus mirabilis* (0.81 [0.24–0.98]) (**S7 Fig**).

Fig 5. Ceftriaxone resistance patterns in various pathogens.

For ceftazidime, the highest resistance was noted among *Klebsiella pneumoniae* (0.89 [0.64–0.97]), *Acinetobacter baumannii* (0.82 [0.58–0.93]), and *Proteus mirabilis* (0.67 [0.44–0.84]) (**S8 Fig**). Resistance to the fourth-generation cephalosporin, cefepime, was also observed across multiple bacterial species, with *Enterobacter species* (0.91 [0.66–0.98]), *Escherichia coli* (0.86 [0.14–1.00]), *Klebsiella species* (0.73 [0.59–0.83]), and *Citrobacter species* (0.72 [0.47–0.88]) (**S9 Fig**).

Despite the overall high resistance observed among pathogens against specific antibiotics, certain pathogens exhibited a lower pooled resistance prevalence. *Escherichia coli* and *Staphylococcus aureus* showed resistance to cefuroxime (0.38 [0.19–0.60]) and cefoxitin (0.38 [0.26–0.53]), respectively (**S10**–**S11 Figs**). The ESKAPE-E pathogens were tested against meropenem, exhibiting an overall pooled resistance prevalence of 0.11 [0.06–0.19]). Among individual pathogens, *Escherichia coli* showed the lowest resistance (0.04 [0.01–0.10]), followed by *Klebsiella species* (0.07 [0.03–0.15]), *Enterobacter cloacae* (0.07 [0.01–0.37]), *Pseudomonas aeruginosa* (0.30 [0.18–0.46]), and *Staphylococcus aureus* (0.27 [0.07–0.66]) (**Fig 3**). Notably, *Acinetobacter baumannii* exhibited the highest resistance (0.45 [0.27–0.65]). For imipenem, *Klebsiella pneumoniae* and *Escherichia coli* had an overall pooled resistance prevalence of 0.06 [0.02–0.26], with individual resistance rates of (0.08 [0.02–0.26]) and (0.06 [0.02–0.26]), respectively (**S12 Fig**). Similarly, *Klebsiella pneumoniae* and *Escherichia coli* exhibited an overall pooled resistance prevalence of (0.06 [0.02–0.14]) to clindamycin (**S13 Fig**).

In the case of nitrofurantoin, *Staphylococcus aureus*, *Escherichia coli*, and *Klebsiella species* demonstrated an overall pooled resistance prevalence of (0.24 [0.16–0.34]) (**S14 Fig**). The included studies demonstrated moderate to substantial heterogeneity across pathogens and antibiotics, with 76.5% exhibiting high heterogeneity (above 75%).

Fig 6. Meropenem resistance patterns among various pathogens.

Discussion

This systematic review investigated the prevalence of antimicrobial resistance in Tanzania. The findings indicate alarmingly high resistance rates to the *AWaRe (Access, Watch, Reserve)* classes of antibiotics in Tanzania. The ESKAPE-E pathogens have exhibited high resistance to a wide range of these groups of antibiotics, which suggests a significant challenge in treating infections caused by these pathogens in the country (2).

ESKAPE-E pathogens are the leading causes of urinary tract infections, surgical site infections, skin infections, upper and lower respiratory infections, bloodstream infections, and nosocomial infections in Tanzania (10, 50)**.** The current study identified high resistance rates among these pathogens to commonly used *Access group* of antibiotics, including *nitrofurantoin (24%), erythromycin (56%), amoxicillin-clavulanic acid (66%), Tetracycline(67%), and ampicillin (86%).* A study conducted in South Africa and a review conducted in East Africa from 2005 to 2015, involving Uganda, Kenya, Ethiopia, Rwanda, and the Democratic Republic of Congo, reported similar resistance patterns(51,52). These elevated resistance levels significantly compromise treatment efficacy, leading to prolonged illness, increased healthcare costs, and higher mortality rates (6,53).

Considering individual pathogens and specific *Access group* of antibiotics, resistance to *ampicillin* was particularly alarming, with 96% of *Klebsiella pneumoniae*, 94% of *Acinetobacter baumannii*, and 90% of *Escherichia coli* isolates exhibiting resistance. Given that ampicillin is recommended as a treatment option for these pathogens in the Tanzania Standard Treatment Guidelines (54), such high resistance raises concerns about treatment complications and prolonged hospital stays. These findings align with previous studies conducted in South Africa and East African countries (51,52), further emphasising the need for urgent interventions.

Moreover, *Acinetobacter baumannii*, *Proteus mirabilis*, and *Klebsiella pneumoniae* exhibited high resistance rates of 92 %, 87 %, and 85 %, respectively, to *amoxicillin-clavulanic acid*, complicating the effective management of bloodstream infections, wound infections, urinary tract infections (UTIs), upper respiratory infections, and pneumonia(25,50,55–56). Similar resistance patterns have been reported in previous studies(57), highlighting the growing challenge of antimicrobial resistance in those pathogens. However, nitrofurantoin, commonly recommended for UTIs treatment in Tanzania (54), showed relatively lower resistance rates, with *Escherichia coli* (21%), *S. aureus* (24%), and *Klebsiella spp.* (32%). These findings are consistent with those of other studies (52), suggesting that nitrofurantoin remains a viable treatment option for UTIs, although continuous monitoring is essential.

Furthermore, more than half of the samples tested for *erythromycin* susceptibility exhibited resistance, to *Campylobacter spp.* (85%), *Escherichia coli* (61%), and *Staphylococcus aureus* (52%) showed notable resistance levels. This trend aligns with the findings of studies conducted in Kenya (58) and a review conducted in Africa (59), reinforcing concerns regarding the declining effectiveness of erythromycin.

Similarly, the *Watch group* of antibiotics revealed an overall resistance to *sulfonamides (84%)*, *ceftriaxone*(60%), *ceftazidime(55%)*, *cefuroxime(38%),* and *ciprofloxacin(34%).* Ceftriaxone, a crucial antibiotic for severe bloodstream infections, surgical site infections, complicated UTIs, and gastrointestinal infections, has shown higher resistance to a wide range of pathogens. *A. baumannii* demonstrated a resistance of 91%, followed by *Pseudomonas aeruginosa* (85%) and *K. pneumoniae* (74%). These findings are consistent with a review conducted focusing on *A. baumannii* in 2019 (60), which reported similar high resistance levels, further emphasising the limited efficacy of ceftriaxone in treating severe bacterial infections.

Moreover, Ciprofloxacin resistance was assessed among ESKAPE-E pathogens, with more than half of *A. baumannii* demonstrating resistance, whereas other pathogens exhibited resistance rates below 50%. This high resistance in A. *baumannii* may indicate selective pressure due to the widespread use of ciprofloxacin, particularly in the management of urinary tract infections (UTIs), post-operative care, and bloodstream infections (54,61–62). Despite the observed resistance, ciprofloxacin remains effective in treating these infections. However, caution is required to prevent further resistance development through prudent use and antimicrobial stewardship programs.

The *reserved group* of antibiotics, intended for last-resort use, including *carbapenems, amikacin*, *clindamycin,* and *cefepime*, revealed heterogeneous resistance ranging from as low as 6% to as high as 81%. This trend raises concerns about treatment outcomes for complicated cases referred from lower-level facilities, where *Access to group* antibiotics has failed. When analysing resistance by specific antibiotic-pathogen combinations, both *clindamycin* and *imipenem* exhibited relatively low resistance rates against *E. coli* (8%) and *K. pneumoniae* (3%), respectively. The lower resistance observed for these antibiotics can be attributed to restricted access, as they are not available over the counter, thereby reducing misuse and selective pressure (63). These findings align with studies conducted in Uganda and South Africa(64,65), which also reported lower resistance rates to these reserved antibiotics.

Among ESKAPE-E pathogens, *meropenem* demonstrated relatively low resistance, with *E. coli* (4%), *Klebsiella spp.* (7%), and *Enterobacter cloacae* (7%) showing low resistance. However, *A. baumannii* showed notably higher resistance, which may reflect its well-documented ability to develop multidrug resistance (60). These findings underscore the importance of maintaining strict control over the use of *reserved* antibiotics while implementing

continuous surveillance to prevent resistance escalation. Similar trends have been observed in studies conducted in South Africa and Ethiopia (64,66,67), further supporting the need for continuous monitoring. Conversely, *cefepime* and *amikacin* exhibited significantly higher resistance rates, particularly in *E. coli* (86% and 20%, respectively). Alarmingly, elevated resistance was also observed in *Enterobacter spp.* (91% resistant to *cefepime*) and *Proteus spp.* (86% resistant to *amikacin*), suggesting that these previously reserved antibiotics may be losing their efficacy. These findings are similar to those of studies conducted in Iran, USA, India, and Africa (68-71), where higher resistance rates were reported, highlighting the potential regional differences in antibiotic use and resistance patterns.

This review provides valuable insights into the pooled prevalence of antimicrobial resistance in Tanzania. However, this study has some limitations. Most studies were conducted in hospital settings, which may limit the generalisability of the findings to the broader population. Similarly, over half of the studies were conducted in urban areas, particularly in Dar es Salaam and Mwanza.

Conclusion

The current review highlights the critical and troubling rates of antimicrobial resistance among *ESKAPE-E* pathogens in Tanzania, which create significant challenges in the effective management of urinary tract infections (UTIs), upper respiratory tract, skin, bloodstream, pneumonia, and wound infections. The high resistance to the *Access* and *Watch* groups of antibiotics indicates that standard treatment regimens may no longer be reliable, resulting in longer illnesses, increased healthcare expenses, and higher mortality rates. Although resistance levels to reserved antibiotics like *carbapenems, cefepime* and *amikacin* are relatively low, troubling trends have been observed, especially with *A. baumannii, E. coli, Proteus spp* and

Enterobacter spp. This situation emphasises the need to protect these last-resort treatments through rigorous antimicrobial stewardship and regulatory policies, and by revising the Tanzania Standard Treatment Guidelines. Moreover, implementing prescription regulations is essential for combating the ongoing development of antimicrobial resistance.

Abbreviations

ESKAPE-E (*Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter* spp, *Escherichia coli*), **STG** (Standard Treatment Guideline), **NEMLIT** (The National Essential Medicines List of Tanzania), **AMR** (Antimicrobial resistance), **BSI** (bloodstream infections), **SSI** (Surgical Site Infection), *AWaRe* (*Access, Watch, Reserve*), *Access* (Penicillin, Erythromycin, Tetracycline, Nitrofurantoin) *Watch* (Cephalosporins, Ciprofloxacin, Sulphonamides), *Reserve* (Carbapenems, Cefepime, Clindamycin, Amikacin).

Acknowledgement

The authors would like to thank the researchers who published their articles online, without which this review would not have been possible.

Authors contribution

CBK, OB and JM (conceptualization, protocol registration, literature search, full article review, writing the manuscript), JJM (conceptualization, data analysis and interpretation), SM and IM (Screening and data extraction), AML (Screening, data extraction and review) and MK, MM and SA (review of the manuscript)

Funding statement

No funding was received for this review

Data availability

The datasets used in this review are available upon request from the corresponding author. All

relevant data are provided separately as supplementary files.

Competing interests

None declared.

References

1. NFID. Antibiotic Resistance - NFID [Internet]. 2024 [cited 2025 Mar 7]. Available from: https://www.nfid.org/antibiotic-resistance/
2. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021 Oct 1 ;10(10):1310
3. Murray CJL, Ikuta KS, Sharara F. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb;399(10325):629–55
4. WHO. Antimicrobial resistance [Internet]. 2023 [cited 2025 Mar 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
5. Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of Antibiotic Resistance Transmissionin Low- and Middle-Income Countriesfrom a "One Health" Perspective-A Review. Antibiotics (Basel). 2020 Jul;9(7)
6. Camara N, Moremi N, Mghamba J, Eliakimu E, Shumba E, Ondoa P, et al. Surveillance of antimicrobial resistance in human health in Tanzania: 2016-2021. Afr J Lab Med. 2023;12(1):2053
7. Katyali D, Kawau G, Blomberg B, Manyahi J. Antibiotic use at a tertiary hospital in Tanzania: findings from a point prevalence survey. Antimicrob Resist Infect Control. 2023;12(1):112
8. Sindato C, Mboera LEG, Katale BZ, Frumence G, Kimera S, Clark TG, et al. Knowledge, attitudes and practices regarding antimicrobial use and resistance among communities of Ilala, Kilosa and Kibaha districts of Tanzania. Antimicrob Resist Infect Control. 2020;9:1–17
9. URT. The 2022 Population and House Census. Initial results. 2022
10. Silago V, Oravcova K, Matthews L, Mshana SE, Claus H, Seni J. Epidemiology and antimicrobial resistance trends of pathogens causing urinary tract infections in Mwanza, Tanzania: A comparative study during and after the implementation of the National Action Plan on Antimicrobial Resistance (2017-2022). International Journal of Infectious Diseases. 2024;147:107208
11. Frumence G, Mboera LEG, Katale BZ, Sindato C, Kimera S, Durrance-Bagale A, et al. Policy actors and human and animal health practitioners' perceptions of antimicrobial use

and resistance in Tanzania: A qualitative study. J Glob Antimicrob Resist. 2021 Jun;25:40–7

12. Emgård M, Mwangi R, Mayo C, Mshana E, Nkini G, Andersson R, et al. Tanzanian primary healthcare workers' experiences of antibiotic prescription and understanding of antibiotic resistance in common childhood infections: a qualitative phenomenographic study. Antimicrob Resist Infect Control. 2021;10:1–15

13. Mkinga DA, Lyamuya FS. Aetiology and Antimicrobial Susceptibility Pattern of Bacteria Pathogens from Hospitalised Adult Patients at a Tertiary Care Hospital in North Eastern Tanzania. East Africa Science. 2022 Mar 31;4(1):54–61

14. Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47(1):46

15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The BMJ. 2021;372:1–9

16. Covidence. Covidence - Better systematic review management [Internet]. 2025 [cited 2025 Mar 27]. Available from: https://www.covidence.org/

17. JBI. Checklist for Analytical Cross Sectional Studies Critical Appraisal Checklist for Analytical Cross Sectional Studies 2. 2017 [cited 2025 Mar 14]; Available from: http://joannabriggs.org/research/critical-appraisal-tools.htmlwww.joannabriggs.org

18. Barker TH, Stone JC, Sears K, Klugar M, Leonardi-Bee J, Tufanaru C, et al. Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process. JBI Evid Synth. 2023 Nov 22;21(3):478–93

19. Dettori JR, Norvell DC, Chapman JR. Seeing the Forest by Looking at the Trees: How to Interpret a Meta-Analysis Forest Plot. Global Spine J. 2021 May 3;11(4):614–6

20. Viechtbauer W. Conducting Meta-Analyses inR with the metafor Package. J Stat Softw. 2010;36(3)

21. Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. Cham: Springer International Publishing; 2015

22. Masoud SS, Kovacevich A, Gangji R, Nyawale H, Nyange M, Ntukula A. Extent and resistance patterns of ESKAPE pathogens isolated in pus swabs from hospitalized patients. Canadian Journal of Infectious Diseases and Medical Microbiology. 2022;2022(1):3511306

23. Omar MH, Kilale AM, Rashid HK, Mwakapeje ER, Onoka IM, Gimbi AA. Prevalence and risk factors for extended-spectrum β-lactamase producing antimicrobial-resistant E. coli in urinary tract infections among inpatients in the tertiary hospitals in Zanzibar (Tanzania): a prospective cross-sectional study. Pan Afr Med J. 2024;47:193

24. Joachim A, Moyo SJ, Nkinda L, Majigo M, Mmbaga E, Mbembati N, et al. Prevalence of methicillin-resistant Staphylococcus aureus carriage on admission among patients attending regional hospitals in Dar es Salaam, Tanzania. BMC Res Notes. 2017 Aug;10(1):417

25. Manyahi J, Matee MI, Majigo M, Moyo S, Mshana SE, Lyamuya EF. Predominance of multi-drug resistant bacterial pathogens causing surgical site infections in Muhimbili National Hospital, Tanzania. BMC Res Notes. 2014;7:1–7

26. Moyo SJ, Aboud S, Blomberg B, Mkopi N, Kasubi M, Manji K, et al. High nasal carriage of methicillin-resistant Staphylococcus aureus among healthy Tanzanian under-5 children. Microbial Drug Resistance. 2014;20(1):82–8

27. Marwa KJ, Mushi MF, Konje E, Alele PE, Kidola J, Mirambo MM. Resistance to Cotrimoxazole and Other Antimicrobials among Isolates from HIV/AIDS and Non☐HIV/AIDS Patients at Bugando Medical Centre, Mwanza, Tanzania. AIDS Res Treat. 2015;2015(1):103874

28. Komba EVG, Mdegela RH, Msoffe PLM, Nielsen LN, Ingmer H. Prevalence, Antimicrobial Resistance and Risk Factors for Thermophilic Campylobacter Infections in Symptomatic and Asymptomatic Humans in Tanzania. Zoonoses Public Health. 2015 Nov;62(7):557–68

29. Ahmed M, Moremi N, Mirambo MM, Hokororo A, Mushi MF, Seni J, et al. Multi-resistant gram negative enteric bacteria causing urinary tract infection among malnourished underfives admitted at a tertiary hospital, northwestern, Tanzania. Ital J Pediatr. 2015;41:1–5

30. Okamo B, Moremi N, Seni J, Mirambo MM, Kidenya BR, Mshana SE. Prevalence and antimicrobial susceptibility profiles of Staphylococcus aureus nasal carriage among pre-clinical and clinical medical students in a Tanzanian University. BMC Res Notes. 2016 Jan;9:47

31. Moremi N, Claus H, Mshana SE. Antimicrobial resistance pattern: a report of microbiological cultures at a tertiary hospital in Tanzania. BMC Infect Dis. 2016;16(1):756

32. Tellevik MG, Blomberg B, Kommedal Ø, Maselle SY, Langeland N, Moyo SJ. High Prevalence of Faecal Carriage of ESBL-Producing Enterobacteriaceae among Children in Dar es Salaam, Tanzania. PLoS One. 2016;11(12):e0168024

33. Seidman JC, Johnson LB, Levens J, Mkocha H, Muñoz B, Silbergeld EK, et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non-pathogenic Escherichia coli from young Tanzanian children. Front Microbiol. 2016;7:1420

34. Ahmed M, Mirambo MM, Mushi MF, Hokororo A, Mshana SE. Bacteremia caused by multidrug-resistant bacteria among hospitalized malnourished children in Mwanza, Tanzania: a cross sectional study. BMC Res Notes. 2017;10:1–5

35. Kumburu HH, Sonda T, Mmbaga BT, Alifrangis M, Lund O, Kibiki G, et al. Patterns of infections, aetiological agents and antimicrobial resistance at a tertiary care hospital in northern Tanzania. Tropical Medicine & International Health. 2017;22(4):454–64

36. Kiponza R, Balandya B, Majigo M V, Matee M. Laboratory confirmed puerperal sepsis in a national referral hospital in Tanzania: etiological agents and their susceptibility to commonly prescribed antibiotics. BMC Infect Dis. 2019;19:1–7

37. Seni J, Tito JN, Makoye SJ, Mbena H, Alfred HS, van der Meer F, et al. Multicentre evaluation of significant bacteriuria among pregnant women in the cascade of referral healthcare system in North-western Tanzania: Bacterial pathogens, antimicrobial resistance profiles and predictors. J Glob Antimicrob Resist. 2019 Jun;17(11):173–9

38. Emgård M, Msuya SE, Nyombi BM, Mosha D, Gonzales-Siles L, Nordén R, et al. Carriage of penicillin-non-susceptible pneumococci among children in northern Tanzania in the 13-valent pneumococcal vaccine era. International Journal of Infectious Diseases. 2019;81:156–66

39. Madut DB, Rubach MP, Kalengo N, Carugati M, Maze MJ, Morrissey AB, et al. A prospective study of Escherichia coli bloodstream infection among adolescents and adults in northern Tanzania. Trans R Soc Trop Med Hyg. 2020 May;114(5):378–84

40. Daud M, Nyombi B. Antimicrobial Resistance Pattern in Escherichia coli Isolated from Children Admitted at Selected Health Care Facilities in Moshi Municipality, Tanzania. South Asian Journal of Research in Microbiology. 2020;6(3):33–9

41. Kamgobe E, Grote S, Mushi MF, Wilson D, Gandye L, Bader O, et al. Multi-drug resistant facultative pathogenic bacteria colonizing the vagina of pregnant women with premature rupture of membrane, Tanzania. East Africa Science. 2020;2(1):29–35

42. Mikomangwa WP, Bwire GM, Kilonzi M, Mlyuka H, Mutagonda RF, Kibanga W, et al. The existence of high bacterial resistance to some reserved antibiotics in tertiary hospitals in Tanzania: a call to revisit their use. Infect Drug Resist. 2020;1831–8

43. Manyahi J, Kibwana U, Mgimba E, Majigo M. Multi-drug resistant bacteria predict mortality in bloodstream infection in a tertiary setting in Tanzania. PLoS One. 2020;15(3):e0220424

44. Kadigi D, Mosha F, Moyo S, Matee M. Etiology and antimicrobial susceptibility patterns of bacterial agents causing urinary tract infection in children under five years, dar es salaam. Journal of Biotechnology and Immunology. 2020;2(1):2

45. Letara N, Ngocho JS, Karami N, Msuya SE, Nyombi B, Kassam NA, et al. Prevalence and patient related factors associated with Extended-Spectrum Beta-Lactamase producing Escherichia coli and Klebsiella pneumoniae carriage and infection among pediatric patients in Tanzania. Sci Rep. 2021;11(1):22759

46. Sangeda RZ, Paul F, Mtweve DM. Prevalence of urinary tract infections and antibiogram of uropathogens isolated from children under five attending Bagamoyo District Hospital in Tanzania: a cross-sectional study. F1000Res. 2021;10:449

47. Manyahi J, Majigo M, Kibwana U, Kamori D, Lyamuya EF. Colonization of Extended-spectrum β-lactamase producing Enterobacterales and meticillin-resistant S. aureus in the intensive care unit at a tertiary hospital in Tanzania: Implications for Infection control and prevention. Infection Prevention in Practice. 2022;4(2):100212

48. Schmider J, Bühler N, Mkwatta H, Lechleiter A, Mlaganile T, Utzinger J, et al. Microbiological characterisation of community-acquired urinary tract infections in Bagamoyo, Tanzania: a prospective study. Trop Med Infect Dis. 2022;7(6):100

49. Silago V, Moremi N, Mtebe M, Komba E, Masoud S, Mgaya FX, et al. Multidrug-resistant uropathogens causing community acquired urinary tract infections among patients attending health facilities in Mwanza and Dar es Salaam, Tanzania. Antibiotics. 2022;11(12):1718

50. Augustine FF, Mgaya XM, Yahya SA, Niccodem EM, Matee MI. An alarming prevalence of multidrug-resistant (MDR) ESKAPE pathogens and other drug-resistant bacteria isolated from patients with bloodstream infections hospitalized at Muhimbili National Hospital in Dar es Salaam, Tanzania. German Journal of Microbiology. 2023 Dec;3(3):7–15

51. Ampaire L, Muhindo A, Orikiriza P, Mwanga-Amumpaire J, Bebell L, Boum Y. A review of antimicrobial resistance in East Africa. Vol. 5, African Journal of Laboratory Medicine. AOSIS OpenJournals Publishing AOSIS (Pty) Ltd; 2016

52. Mthombeni TC, Burger JR, Lubbe MS, Julyan M, Lekalakala-Mokaba MR. ESKAPE pathogen incidence and antibiotic resistance in patients with bloodstream infections at a

referral hospital in Limpopo, South Africa, 2014–2019: A cross-sectional study. Afr J Lab Med. 2024 ;13(1):2519.

53. Oliveira M, Antunes W, Mota S, Madureira-Carvalho Á, Dinis-Oliveira RJ, Dias da Silva D. An Overview of the Recent Advances in Antimicrobial Resistance. Microorganisms 2024, Vol 12, Page 1920 [Internet]. 2024 Sep 21 [cited 2025 Mar 12];12(9):1920. Available from: https://www.mdpi.com/2076-2607/12/9/1920/htm

54. URT. The united republic of Tanzania standard treatment guidelines and national essential medicines list for Tanzania mainland. 2021

55. Mlugu EM, Mohamedi JA, Sangeda RZ, Mwambete KD. Prevalence of urinary tract infection and antimicrobial resistance patterns of uropathogens with biofilm forming capacity among outpatients in morogoro, Tanzania: a cross-sectional study. BMC Infect Dis. 2023;23(1)

56. Muro RP, Masoza TS, Kasanga G, Kayange N, Kidenya BR. Predictors and outcome of first line treatment failure among under-five children with community acquired severe pneumonia at Bugando Medical Centre, Mwanza, Tanzania: A prospective cohort study. Vol. 15, PLoS ONE. Public Library of Science; 2020

57. Ayobami O, Brinkwirth S, Eckmanns T, Markwart R. Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: a systematic review and meta-analysis. Emerg Microbes Infect. 2022;11(1):443–51

58. Awuor SO, Omwenga EO, Mariita RM, Musyoki S, Musila J. Monitoring the battleground: Antimicrobial resistance, antibiofilm patterns, and virulence factors of wound bacterial isolates from patients in hospital system. 2023. Available from: https://www.microbiologyresearch.org/content/journal/acmi/10.1099/acmi.0.000613.v1

59. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, et al. Antimicrobial resistance in Africa: A systematic review. BMC Infect Dis. 2017;17(1)

60. Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY. The Mechanisms of Disease Caused by Acinetobacter baumannii. Front Microbiol. 2019;10(JULY)

61. Brown PD. Ciprofloxacin for the management of urinary tract infection. Womens Health (Lond) [Internet]. 2006 Jul [cited 2025 Mar 14];2(4):509–16. Available from: https://pubmed.ncbi.nlm.nih.gov/19803958/

62. Thai T, Salisbury BH, Zito PM. Ciprofloxacin. StatPearls Publishing [Internet]. 2023 Aug 28 [cited 2025 Mar 14];(2023 Jan-)

63. URT. The National Action Plan on Antimicrobial Resistance 2023-2028. 2023.

64. Ramsamy Y, Essack SY, Sartorius B, Patel M, Mlisana KP. Antibiotic resistance trends of ESKAPE pathogens in Kwazulu-Natal, South Africa: A five-year retrospective analysis. Afr J Lab Med . 2018 ;7(2):887

65. Namubiru S, Migisha R, Okello PE, Simbwa B, Kabami Z, Agaba B, et al. Increasing trends of antibiotic resistance in Uganda: analysis of the national antimicrobial resistance surveillance data, 2018–2021. BMC Infect Dis. 2024 Dec 1 ;24(1):1–8

66. Kitaba AA, Bonger ZT, Beyene D, Ayenew Z, Tsige E, Kefale TA, et al. Antimicrobial resistance trends in clinical Escherichia coli and Klebsiella pneumoniae in Ethiopia. Afr J Lab Med . 2024 ;13(1):2268

67. Greatorex B, Oosthuizen G. Organisms cultured and resistance patterns seen in a secondary referral centre ICU and burns unit. Southern African Journal of Critical Care (Online). 2015 ;31(1):12–5

68. Raeispour M, Ranjbar R. Antibiotic resistance, virulence factors and genotyping of Uropathogenic Escherichia coli strains. Antimicrob Resist Infect Control . 2018 Oct 3;7(1):1–9

69. Grossman TH. Tetracycline Antibiotics and Resistance. Cold Spring Harb Perspect Med. 2016 Apr 1 ;6(4): a025387

70. Handa VL, Patel BN, Bhattacharya DA, Kothari RK, Kavathia DG, Vyas BRM. A study of antibiotic resistance pattern of clinical bacterial pathogens isolated from patients in a tertiary care hospital. Front Microbiol . 2024 ;15:1383989

71. Beig M, Aghamohammad S, Majidzadeh N, Asforooshani MK, Rezaie N, Abed S, et al. Antibiotic resistance rates in hypervirulent Klebsiella pneumoniae strains: A systematic review and meta-analysis. J Glob Antimicrob Resist. 2024 Sep 1;38:376–88

Supporting information

S1 Table. Quality Assessment Table

S1 Fig. Ampicillin resistance patterns among various pathogens

S2 Fig. Erythromycin resistance patterns among various pathogens

S3 Fig. Ciprofloxacin resistance patterns among various pathogens

S4 Fig. Amikacin resistance patterns among various pathogens

S5 Fig. Tetracycline resistance patterns among various pathogens

S6 Fig. Trimethoprim-sulphamethoxazole resistance patterns among various pathogens

S7 Fig. Cefotaxime resistance patterns among various pathogens

S8 Fig. Ceftazidime resistance patterns among various pathogens

S9 Fig. Cefepime resistance patterns among various pathogens

S10 Fig. Cefuroxime resistance patterns with E.coli

S11 Fig. Cefoxitin resistance patterns among various pathogens

S12 Fig. Imipenem resistance patterns among various pathogens

S13 Fig. Clindamycin resistance patterns among various pathogens

S14 Fig. Nitrofurantoin resistance patterns among various pathogens

S1 Fig A1. PRISMA 2020 Checklist